Are the United-States on the way for a vaccine against coronavirus? American laboratory Moderna announced this Monday May 18th to have “positive interim data” as for the first phase of a clinical trial for a vaccine project against Covid-19. What does it mean? It means that after injecting the currently studied vaccine, called mRNA-1273, some patients’ bodies elicited an encouraging immune response “of the magnitude caused by natural infection” according to our peers from Challenges, quoting the laboratory’s released.
“These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection” Tal Zaks, M.D., Ph.D., Chief Medical Officer at Moderna. What is this clinical trial about? Carried out by NIH, it includes 45 patients divided into three groups of 15, each given three different doses of vaccines, in one or two shots. All in all, 40 volunteers of the clinical trial elicited this immune response and eight of them developed neutralizing antibodies. A first phase which official results are yet expected in order to move on to the next step and produce a vaccine at the end.
The second phase must start soon, as the last and third phase, before potential production of the vaccine could start in July, according to Moderna, if results are convincing. “the Moderna team continues to focus on moving as fast as safely possible to start our pivotal Phase 3 study in July” Chief Executive Officer at Moderna Stéphane Bancel explains. The last phase, that many searchers and leaders will thoroughly browse, to know if this is an effective vaccine or not.